Desflurane-induced and ischaemic postconditioning against myocardial infarction are mediated by Pim-1 kinase by Stumpner, J. et al.
Desflurane-induced and ischaemic postconditioning
against myocardial infarction are mediated by
Pim-1 kinase
J. Stumpner1, T. M. Smul1, A. Redel1,2, T. Hilz1, T. Tischer-Zeitz1, H. Eisenbarth3, M. A. Schick1, F. Kehl4,
N. Roewer1 and M. Lange1,5
1Department of Anaesthesia and Critical Care, University of Würzburg, Würzburg, Germany, 2Department of Anesthesia, University of
Regensburg, Regensburg, Germany, 3Department of Forensic Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany,
4Department of Anesthesiology and Critical Care, Hospital of Karlsruhe, Karlsruhe, Germany and 5Department of Anesthesia and Critical Care
Medicine, Mathias-Spital Rheine, Germany
Background: Anaesthetic-induced (APOST) and ischaemic
postconditioning (IPOST) against myocardial infarction are
mediated via phosphatidylinositol-3-kinase/Akt. Pim-1 kinase is
acting downstreamofAkt and has recently been demonstrated to
enhance cardiomyocyte survival. We tested the hypothesis that
both APOST and IPOST are mediated by Pim-1 kinase.
Methods: Pentobarbital-anaesthetized male C57BL/6 mice
were subjected to 45-min coronary artery occlusion (CAO) and
3-h reperfusion. Animals received either no intervention, the
Pim-1 kinase inhibitor II (10 mg/g intraperitoneally) or its
vehicle dimethy sulfoxide (10 ml/g intraperitoneally). Three
minutes prior to the end of CAO, 1.0 minimum alveolar concen-
tration desflurane was administered for 18 min alone or in com-
bination with Pim-1 kinase inhibitor II. IPOST was induced by
three cycles of each 10-s ischaemia/reperfusion, and animals
received either IPOST alone or in combination with Pim-1 kinase
inhibitor II. Infarct size was determined with triphenyltetrazo-
lium chloride and area at risk with Evans blue. Protein expres-
sion of Pim-1 kinase, Bad, phospho-BadSer112 and B-cell
lymphoma 2 was determined using Western immunoblotting
analysis.
Results: Infarct size in control animals (CON) was 46  3%.
Dimethylsulfoxide (47  3%) and Pim-1 kinase inhibitor II
(44  5%) did not significantly reduce infarct size. Desflurane
(16  2%*; *P < 0.05 vs. CON) and IPOST (21  2%*) signifi-
cantly reduced infarct size compared with CON. Inhibition of
Pim-1 kinase abolished desflurane-induced postconditioning
(46  4%) and IPOST (44  5%). Western blot analysis revealed
that only desflurane enhances phosphorylation of Bad at serine
112 that was abrogated by Pim-1 kinase inhibitor II.
Conclusion: These data suggest that Pim-1 kinase mediates
both desflurane-induced postconditioning and IPOST in mice.
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Although early myocardial reperfusion isregarded the most effective strategy to treat
acute myocardial ischaemia, considerable evidence
has accumulated that myocardial reperfusion itself
causes cardiomyocyte death.1,2 This is known as
lethal reperfusion injury. Myocardial reperfusion is
estimated to cause 50% of myocardial infarct size
(IS) as a result of ischaemia/reperfusion injury.2
Further support to this concept was provided by the
study of Zhao et al., who demonstrated that three
cycles of each 30-s reperfusion/ischaemia immedi-
ately after coronary artery occlusion (CAO)_
reduced myocardial IS up to 40% in dogs.3 This phe-
nomenon was termed ischaemic postconditioning
(IPOST).3 IPOST has been demonstrated to reduce
myocardial IS among others in dogs,3 rabbits4 and
mice.5–7 In humans, IPOST has been shown to
reduce myocardial IS as assessed 6 months after
acute myocardial infarction and to improve left ven-
tricular ejection fraction after 1 year.8
Cardioprotective properties of volatile anaesthet-
ics during early reperfusion are known for more
than a decade since the first description of Schlack’s
group.9 Later, this phenomenon was termed
anaesthetic-induced postconditioning (APOST).10
APOST reduces myocardial IS,5,10,11 improves left
ventricular function after myocardial ischaemia12
and has been demonstrated to occur in humans.13
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Isoflurane, sevoflurane and desflurane (DES) are
equally effective to reduce myocardial IS in mice
in vivo.5
Both IPOST andAPOST afford their cardioprotec-
tive properties via reduction of reperfusion injury
and are mediated via phosphatidylinositol-3-kinase
(PI3K)/Akt10,14,15 as a part of the reperfusion injury
salvage kinase (RISK) pathway.16
The serine/threonine kinase Pim-1 belongs to the
family of calcium/calmodulin-dependent protein
kinases (CaMK).17 DES-induced postconditioning is
mediated by CaMKII in rabbits in vivo.11 Pim-1
kinase has recently been described to act down-
stream of PI3K/Akt in cardiac myocytes.18 Genetic-
induced overexpression of Pim-1 confers anti-
apoptotic18 and antihypertrophic effects,19 and
reduces myocardial IS.18 Moreover, genetic engi-
neering of cardiac progenitor cells with Pim-1
kinase has been described to improve cellular viabil-
ity, proliferation and regeneration after acute myo-
cardial infarction.20 More recently, our group
demonstrated a crucial role for Pim-1 kinase in both
DES-induced and ischaemic preconditioning (IPC)
against myocardial infarction.21
However, whether Pim-1 kinase is involved in
APOST and IPOST against myocardial infarction
has not been investigated to date. Therefore, we
tested the hypothesis that APOST and IPOST are
mediated via Pim-1 kinase in mice in vivo.
Methods
Ethical approval
All experimental procedures used in this investiga-
tion were reviewed and approved by the Animal
Care and Use Committee of the Government of
Lower Franconia, Bavaria, Germany. All experi-
ments were in accordance with the Guide for the
Care and Use of Laboratory Animals,22 and con-
formed to the Guiding Principles in the Care and
Use of Animals of the American Physiological
Society.
Instrumentation and surgical procedures
Male C57BL/6 mice (10–12 weeks old) were pur-
chased from Harlan laboratories (Horst, the Nether-
lands). Animals were housed under controlled
conditions (22 °C, 55–65% humidity, 12-h light-dark
cycle), and were allowed free access to water and a
standard laboratory chow. Instrumentation and sur-
gical procedures were performed, as described pre-
viously.23 Briefly, mice were anaesthetized with an
intraperitoneal injection of 60 mg/g sodium pento-
barbital (Merial, Hallbergmoos, Germany), and
repeated intraperitoneal injections were given as
needed to maintain anaesthesia. Rectal temperature
was maintained at 37.0 0.1 °C using a servo-
controlled heating-pad (FMI, Seeheim, Germany).
After intubation of the trachea, animals were venti-
lated with 50%/50% air-oxygen mixture using a
small rodent ventilator (SAR-P 830, CWE, Inc.,
Ardmore, PA, USA) operating in pressure-
controlled mode. A three-lead needle-probe electro-
cardiogram (ECG) was attached to continuously
monitor heart rate and ST segment elevation. Saline-
filled polyethylen (PE) catheters were placed into
the right common carotid artery for measurement of
mean arterial blood pressure and into the right
jugular vein for continuous fluid administration
(20 ml/g/h). A left thoracotomy at the fourth inter-
costal space was performed, and the left anterior
descending coronary artery (LAD) was exposed.
CAO was achieved using the hanging weight sys-
tem23,24 and was verified by ECG ST segment eleva-
tion and paleness of the myocardial area at risk
(AAR). Adequate reperfusion was verified by epi-
cardial hyperaemia and reversion of ECG changes.
Experimental protocol
Animals were randomly assigned to seven groups
to investigate the role of Pim-1 kinase in ischaemic
and DES-induced postconditioning. Group size was
n = 8 in each group. The experimental protocol is
illustrated in Figure 1.
After completion of surgical procedures, all mice
were allowed a 30-min equilibration period. Myo-
cardial ischaemia was induced by 45-min CAO fol-
lowed by 3 h of reperfusion. Control animals (CON)
received no additional treatment. In group 2
[dimethyl sulfoxide (DMSO)], the vehicle DMSO
(10 ml/g) was injected intraperitoneally 5 min prior
to the end of CAO. In group 3 [Pim-1 kinase inhibi-
tor II (PIM-Inh.II)], the selective25 Pim-1 kinase
inhibitor 2-hydroxy-3-cyano-4-phenyl-6-(3-bromo-
6-hydroxyphenyl)pyridine (PIM-Inh.II, 10 mg/g,
dissolved in DMSO; Merck, Darmstadt, Germany)
was administered intraperitoneally 5 min prior to
the end of CAO. DES was administered at a concen-
tration of 1.0 minimum alveolar concentration
(MAC, 7.5 Vol%26) for 18 min starting 3 min prior to
the onset of reperfusion. This type of administration
was chosen because the first minute of reperfusion
after CAO is most probably critical for postcondi-
tioning’s success.27 Initiation of DES administration
before reperfusion guaranteed an effective level of
1.0 MAC DES with the onset of reperfusion.
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Animals of group 5 received PIM-Inh.II in combina-
tion with DES (DES+PIM-Inh.II). IPOST was
induced by three cycles of each 10-s ischaemia and
reperfusion immediately after CAO. In group 7,
animals received PIM-Inh.II in combination with
IPOST (IPOST+PIM-Inh.II).
Measurement of myocardial IS
Myocardial IS and AAR were determined using
methods described previously.23 Briefly, after 3 h of
reperfusion, the LAD was re-occluded and 1 ml
Evans blue (0.1 g/ml, Sigma-Aldrich, Taufkirchen,
Germany) was slowly injected into the carotid
artery. After intraperitoneal injection of a lethal dose
of sodium pentobarbital (150 mg/g), the heart was
rapidly excised. The left ventricle was separated and
cut into 7–8 transversal slices of 1-mm thickness.
Slices were incubated in 2,3,5-triphenyltetrazolium
chloride (20 mg/ml) for 30 min at 37 °C. After over-
night fixation in 10% formaldehyde, slices were
weighted and digitally photographed. Photographs
were analysed using Adobe Photoshop CS 8.0.1
(Adobe Systems, Inc., San Jose, CA, USA), and the
normal zone, AAR and IS were determined gravito-
planimetrically by an investigator blinded to the
experimental protocol. Animals with anAAR of less
than 20% were excluded from the study.
Western immunoblotting
In a second set of experiments, myocardial tissue
was extracted after 1 h of reperfusion to investigate
effects on the expression of Pim-1 kinase, Bad and
B-cell lymphoma 2 (Bcl-2), and to investigate phos-
phorylation of Bad at serine 112 as a surrogate for
Pim-1 activity using Western immunoblotting
technique.
Mice (n = 4 in each group) received saline (CON),
PIM-Inh.II, DES alone or in combination with
PIM-Inh.II (DES+PIM-Inh.II), and IPOST alone
(IPOST), or in combination with PIM-Inh.II
(IPOST+PIM-Inh.II). One hour after the onset of
reperfusion, hearts were rapidly excised, and the
left ventricle was shock frozen in liquid nitrogen
and stored at -80 °C until further usage. The
samples were homogenized in ice-cold radio-
immunoprecipitation assay buffer [phosphate-
buffered saline (PBS) (Na2HPO4, NaH2PO4, NaCl,
H2O; ph 7.4), 1% Igepal CA-630, 0.5% sodium
desoxycholic acid, 0.1% sodium dodecylsulfate
polyacrylamide; for phospho-samples: protease
inhibitor, NaF 20 mM, sodium vanadate 1 mM in
addition) and centrifuged at 12,000g at 4 °C.
Cytosolic and particulate cell fractions were left
unseparated for further analysis.
Proteins were loaded on 15% polyacrylamide
sodium dodecylsulfate polyacrylamide gels and
were subsequently blotted on nitrocellulose
membranes (Protran, Whatman GmbH, Dassel,
Germany). Nonspecific background was blocked
using 2.5% nonfat milk powder combined with 2.5%
albumin powder from bovine serum in PBS-Tween
20 (1 h at room temperature). Membranes were then
Fig. 1. Schematic diagram illustrating the
experimental protocol of the study. CAO,
coronary artery occlusion; CON, control
group; DMSO, dimethyl sulfoxide
(10 ml/g) intraperitoneal 5 min prior to the
onset of reperfusion; PIM-Inh.II, Pim-1
kinase inhibitor II (10 mg/g) intraperito-
neal 5 min prior to the onset of reperfusion;
DES, desflurane (1.0 minimum alveolar
concentration DES for 18 min starting
3 min prior to the end of CAO);
DES+PIM-Inh.II, PIM-Inh.II (10 mg/g)
intraperitoneal 5 min prior to the end of
CAO and DES (1.0 minimum alveolar
concentration for 18 min); IPOST, ischae-
mic postconditioning (three cycles of each
10 s ischaemia/reperfusion immediately
after the end of CAO); IPOST+PIM-Inh.II,
PIM-Inh.II (10 mg/g) 5 min prior to
IPOST. Triangles indicate time points of
analysis of haemodynamic parameters, as
presented in Table 1.
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incubated with the following antibodies: antiPim-1
kinase 1 : 100 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), antiBad 1 : 100 (Abcam, Cam-
bridge, Great Britain), antiphospho-BadSer112 1 : 500
(Cell Signaling, Danvers, MA, USA), antiBcl-2
1 : 500 (Abcam), mouse antiglyceraldehyde-3-
phosphate dehydrogenase (Millipore, Billerica, MA,
USA) and mouse anti-aB-crystallin 1 : 3000 (Assay
Designs, Ann Arbor, MI, USA), respectively.
The protein bands were detected using enhanced
chemiluminescent® detection reagent (GE Health-
care, Buckinghamshire, UK) and visualized on an
X-ray film. The films were scanned and optical
density was determined using ImageJ software
(NIH, Bethesda, MD, USA). Optical density of the
target protein was normalized to its loading control
expression. Glyceraldehyde-3-phosphate dehydro-
genase served as the loading control for Bad,
phospho-BadSer112 and Bcl-2, and aB-crystallin
served as the loading control for Pim-1 kinase,
respectively. The control group ratio was set as
100%.
Data acquisition and statistical analysis
ECG, systemic haemodynamic parameters and body
temperature were continuously recorded and ana-
lysed on a personal computer (Fujitsu Siemens,
Augsburg, Germany) using a haemodynamic data
acquisition and analysis software (Notocord® hem
3.5, Croissy-sur-Seine, France).
Concluding from other studies on the same
experimental model,21,23,28 we expected a myocardial
IS of 50% (IS/AAR). Power analysis revealed a
group size of n = 8 to detect a reduction in means of
15% with a power of 0.8 at a a-level of 0.05. Statis-
tical analyses were done by analysis of variance
(ANOVA), which were based on two-tailed F-tests
for comparison of components of the factors’ total
deviation. Analyses for body weight, left ventricle
weight, left ventricle weight/body weight, AAR, IS,
IS/left ventricle and AAR/left ventricle were per-
formed using one-wayANOVA, including the factor
treatment (CON vs. DMSO vs. PIM-Inh.II vs. DES
vs. DES+PIM-Inh.II vs. IPOST vs. IPOST+PIM-
Inh.II) and post hoc Duncan’s test for significant
main effects and interactions. Analysis for densit-
ometry was also performed using one-way ANOVA
including the factor treatment (CON vs. PIM-Inh.II
vs. DES vs. DES+PIM-Inh.II vs. IPOST vs.
IPOST+PIM-Inh.II) and post hoc Duncan’s test for
significant main effects and interactions. Analysis of
haemodynamic data was performed by a 7 ¥ 7
ANOVA for repeated measures, including the
between factor treatment (CON vs. DMSO vs. PIM-
Inh.II vs. DES vs. DES+PIM-Inh.II vs. IPOST vs.
IPOST+PIM-Inh.II) and the within factor time point
(baseline vs. PreCAO vs. CAO vs. POST vs. reper-
fusion 60 min vs. reperfusion 120 min vs. reper-
fusion 180 min). In case of any significant main
effects or interactions, post hoc one-way ANOVAs
were conducted for each group and each time point,
where a Bonferroni correction of a was performed.
Statistical analysis of data was performed using SPSS
16.0 software (The Apache Software Foundation,
Forest Hill, MD, USA). Changes in means were con-
sidered statistically significant when P < 0.05. Data
are presented as mean standard error of the
mean.
Results
A total of 86 mice were included to the study.
Sixty-two mice were assigned to the ischaemia-
reperfusion experiments to obtain 56 successful
experiments. Six animals were excluded because of
pump failure during CAO (one in the DMSO group,
one in the PIM-Inh.II group, one in the DES+PIM-
Inh.II group, one in the IPOST group, two in the
IPOST+PIM-Inh.II group). Twenty-four mice were
used to measure protein expression using Western
immunoblotting technique.
Haemodynamic parameters, AAR
Haemodynamic parameters at baseline and AAR
were not different among groups (Tables 1 and 2).
MAP was significantly decreased compared with
baseline values during CAO in two groups (DMSO
and DES). In the PIM-Inh.II group, MAPwas signifi-
cantly decreased compared with the control group
after 120 min of reperfusion.
Myocardial IS
Myocardial IS (IS/AAR) was 46%  3% in control
group (Fig. 2). PIM-Inh.II (44% 5%) alone and its
vehicle DMSO (47% 3%) alone did not reduce
myocardial IS. A 15-min administration of 1.0 MAC
DES during early reperfusion (DES; 16% 2%;
P < 0.05 vs. control group) significantly reduced
myocardial IS compared with control group.
Inhibition of Pim-1 kinase using PIM-Inh.II com-
pletely abolished DES-induced postconditioning
(DES+PIM-Inh.II; 46%  4%). IPOST induced by
three cycles of each 10-s ischaemia and reperfusion
reduced myocardial IS to 21% 2% (IPOST;
P < 0.05 vs. control group, PIM-Inh.II and
IPOST+PIM-Inh.II). Similar to DES-induced post-
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conditioning, IPOST was completely abolished
by application of PIM-Inh.II (IPOST+PIM-Inh.II;
44%  5%).
Western immunoblotting
Total Pim-1 kinase protein expression (Fig. 3) as well
as total Bad expression (Fig. 4A) was not affected by
any of the study drugs. DES did not significantly
increase phosphorylation of Bad at serine 112. DES-
induced phosphorylation of Bad at serine 112 was
significantly reduced by PIM-Inh.II (Fig. 4B).
Expression of Bcl-2 protein was not affected by any
intervention (Fig. 5).
Discussion
This study investigated the role of Pim-1 kinase in
the signalling cascade of ischaemic and DES-
induced postconditioning in amurine in vivomodel
of acute myocardial infarction. Both 15-min admin-
istration of 1 MAC DES during early reperfusion
and three cycles of each 10-s reperfusion/ischaemia
immediately after prolonged myocardial ischaemia
exerted remarkable cardioprotective effects, repre-
sented by a pronounced reduction in myocardial IS.
These results are in line with findings from various
other investigations regarding either APOST5,11,29 or
Table 1
Systemic haemodynamics.
HR (min-1) BL PreCAO CAO POST Reperfusion
60 min 120 min 180 min
CON 463  19 462  20 474  21 473  16 473  11 455  20 470  10
DMSO 486  17 477  11 471  14 483  16 467  11 463  6 463  18
PIM-Inh.II 471  13 465  25 458  8 480  19 482  12 480  14 489  8
DES 451  7 461  7 457  14 434  5 439  6 446  10 460  15
DES+PIM-Inh.II 479  13 466  14 471  10 478  13 493  10 484  10 484  8
IPOST 455  12 443  10 436  6 447  9 434  14 452  15 447  14
IPOST+PIM-Inh.II 467  15 452  15 470  14 488  16 445  30 480  16 494  11
MAP (mmHg)
CON 72  3 66  5 60  2 70  4 71  4 68  4 66  6
DMSO 71  5 70  6 63  5* 67  7 70  5 67  4 64  3
PIM-Inh.II 70  5 67  5 58  6 58  6 59  3 54  1† 56  3
DES 69  2 68  2 58  3* 63  4 65  4 64  3 68  3
DES+PIM-Inh.II 73  2 68  3 67  2 70  2 64  4 64  3 72  6
IPOST 71  5 66  4 62  3 67  3 68  4 65  3 66  5
IPOST+PIM-Inh.II 74  4 71  4 63  4 60  4 66  3 68  4 67  4
Data are mean  SEM.
Data were analysed during baseline period (BL), before (PreCAO) and during (CAO) CAO, during early reperfusion period (POST) and
60, 120 and 180 min after the onset of reperfusion, as indicated by triangles in Figure 1.
*Significantly (P < 0.05) different from BL.
†Significantly (P < 0.05) different from CON.
HR, heart rate; MAP, mean arterial pressure; CON, control; DMSO, dimethyl sulfoxide; PIM-Inh.II, Pim-1 kinase inhibitor II; DES,
desflurane; IPOST, ischaemic postconditioning; CAO, coronary artery occlusion; SEM, standard error of the mean.
Table 2
Body weight and planimetry.
n BW [g] LV [mg] LV/BW [%] AAR [mg] IS [mg] IS/LV [%] AAR/LV [%]
CON 8 25.4  0.7 70.3  2.8 0.28  0.01 25.1  2.6 11.4  1.2 16.0  1.2 35.3  2.6
DMSO 8 26.6  1.0 77.3  3.1 0.29  0.01 25.0  2.1 11.9  1.3 15.4  1.6 32.5  2.6
PIM-Inh.II 8 26.8  1.4 75.9  5.2 0.28  0.01 23.5  1.8 10.5  1.7 13.7  1.7 31.1  1.5
DES 8 24.5  1.2 68.7  5.4 0.28  0.01 21.6  2.3 3.5  0.7*† 5.1  0.9*† 31.3  1.9
DES+PIM-Inh.II 8 25.9  1.1 76.6  4.2 0.30  0.01 26.7  2.8 12.1  1.7 16.2  2.7 36.0  5.1
IPOST 8 26.0  0.4 72.9  2.2 0.28  0.01 21.6  2.5 4.3  0.5*‡ 6.0  0.6*‡ 29.6  3.2
IPOST+PIM-Inh.II 8 26.3  1.1 75.6  3.7 0.29  0.01 23.0  1.2 10.3  1.4 13.5  1.5 30.7  1.7
Data are mean  SEM.
*Significantly (P < 0.05) different from CON. †Significantly (P < 0.05) different from DES+PIM-Inh.II. ‡Significantly (P < 0.05) different
from IPOST+PIM-Inh.II.
BW, body weight; LV, left ventricle; AAR, area at risk; IS, infarct size; CON, control; DMSO, dimethyl sulfoxide; DES, desflurane;
PIM-Inh.II, Pim-1 kinase inhibitor II; IPOST, ischaemic postconditioning; SEM, standard error of the mean.
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IPOST,5–7,29 and provide further evidence that
APOST and IPOST are promising strategies to alle-
viate cardiac ischaemia/reperfusion injury. In this
study, DES and IPOST reduced myocardial IS to a
similar extent. Our results confirm results from
other investigations either in rabbits29 or mice.5,6
A major finding of the present study is that block-
ade of Pim-1 kinase using the highly selective25
PIM-Inh.II completely abolishes DES-induced post-
conditioning and IPOST against myocardial infarc-
tion. The dosage of 10 mg/g body weight has
recently been demonstrated to inhibit Pim-1 kinase
activity effectively in mice in vivo.21 Our results
demonstrate a possible role for the serine/threonine
kinase Pim-1 in the signalling pathway of APOST
and IPOST. Regarding DES, the present results are
similar to the previous finding that blockade of
Pim-1 kinase completely abolishes DES-induced
preconditioning,21 indicating a similar signal trans-
duction pathway of DES-induced preconditioning
andDES-induced postconditioning. In contrast with
IPC that was only partially blocked by Pim-1 inhibi-
tion,21 IPOST is completely abolished by Pim-1
blockade. This might imply differences in the exact
role of Pim-1 kinase in the signalling cascades of IPC
and IPOST. Further studies are required to reveal
these possible differences.
Considerable evidence has accumulated that the
serine/threonine kinase Pim-1 exerts relevant car-
dioprotective properties. Muraski et al. demon-
strated a crucial role for Pim-1 in the regulation of
cardiomyocyte survival downstream of Akt,18 which
itself is a well-known mediator of ischaemic14 and
APOST10 as a part of the RISK pathway.16 Transgenic
animals with myocardial overexpression of Pim-1
kinase exhibit less myocardial ISs18 and are pro-
tected from remodelling following transaortic
constriction.19 More recently, the same group dem-
onstrated that female mice that receive cardiac pro-
genitor cells overexpressing Pim-1 kinase show
improved ventricular function and reducedmyocar-
dial IS.20 Additionally, Pim-1 kinase increases
expression of the sarco/endoplasmatic reticulum
Ca2+-adenosine triphosphatase,18 which might be
involved in the prevention of cardiomyocyte
calcium overload during myocardial reperfusion.
Furthermore, it has been reported that the highly
sequence homologous and structurally similar
Fig. 2. Cardioprotection by desflurane (DES)-induced and ischae-
mic postconditioning (IPOST) is completely abolished by pharma-
cological blockade of Pim-1 kinase. Myocardial infarct size (IS)
expressed as percentage of left ventricular area at risk (AAR).
Values are mean  standard error of the mean. n = 8 in each
group. *significantly (P < 0.05) different from control (CON) and
Pim-1 kinase inhibitor II (PIM-Inh.II). #significantly (P < 0.05)
different from DES+PIM-Inh.II. ‡Significantly (P < 0.05) different
from IPOST+PIM-Inh.II. Mice received either no intervention
(CON), dimethyl sulfoxide (DMSO), PIM-Inh.II), DES alone or
in combination with PIM-Inh.II (DES+PIM-Inh.II), and IPOST
either alone or in combination with PIM-Inh.II (IPOST+PIM-
Inh.II).
Fig. 3. Myocardial expression of Pim-1 kinase is not affected by
DES-induced and IPOST. Western blot analysis of myocardial
expression of Pim-1 kinase. Results are presented as representative
original immunoblottings and average densitometric results as
percentage of control (n = 4 per group). CON, control group; PIM-
Inh.II, Pim-1 kinase inhibitor II (10 mg/g); DES, desflurane (1.0
minimum alveolar concentration); DES+PIM-Inh.II, PIM-Inh.II
in combination with DES; IPOST, ischaemic postconditioning
(three cycles of each 10-s ischaemia/reperfusion); IPOST+PIM-
Inh.II, PIM-Inh.II in combination with IPOST.
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Pim-3 kinase protects against cardiomyocyte apop-
tosis after anoxia/re-oxygenation in rat neonatal
cardiac myocytes.30 Thus, the results of the present
study provide further evidence that Pim-1 kinase
might be a promising target to alleviate the detri-
mental effects of cardiac ischaemia/reperfusion
injury.
We did not observe differences in Pim-1 expres-
sion in whole cell lysates among groups that could
have affected our results. These findings confirm
results from our previous study.21 A recent investi-
gation in isolated rat hearts demonstrated a
decreased Pim-1 expression in the cytosolic fraction
after ischaemia/reperfusion alone.31 This decrease
was attenuated by IPOST, possibly indicating
changes in the intracellular distribution of Pim-1
kinase induced by IPOST.31 The differences between
both studies might be, most probably, due to differ-
ent cell fractions that were analysed (cytosolic frac-
tion vs. whole cell lysate) or due to a different
experimental model (isolated rat heart vs. in vivo
mouse heart), a different I/R protocol (30-min
global ischaemia/120-min reperfusion vs. 45-min
LAD occlusion/60-min reperfusion) or a different
postconditioning protocol (five cycles of each 10-s
reperfusion/ischaemia vs. three cycles of each 10-s
reperfusion/ischaemia). Thus, our study and
Fig. 4. DES-induced phosphorylation of Bad at serine 112 is reduced by blockade of Pim-1 kinase. Western blot analysis of myocardial
expression of Bad (A) and phospho-BadSer112 (B). Results are presented as representative original immunoblottings and average densito-
metric results as percentage of control (n = 4 per group). #significantly (P < 0.05) different from DES. CON, control group; PIM-Inh.II,
Pim-1 kinase inhibitor II (10 mg/g); DES, desflurane (1.0 minimum alveolar concentration); DES+PIM-Inh.II, PIM-Inh.II in combination
with DES; IPOST, ischaemic postconditioning (three cycles of each 10-s ischaemia/reperfusion); IPOST+PIM-Inh.II, PIM-Inh.II in
combination with IPOST.
Fig. 5. Expression of B-cell lymphoma 2 (Bcl-2) is not affected by
any intervention. Western blot analysis of myocardial expression
of Bcl-2. Results are presented as representative original immuno-
blottings and average densitometric results as percentage of control
(n = 4 per group). CON, control group; PIM-Inh.II, Pim-1 kinase
inhibitor II (10 mg/g); DES, desflurane (1.0 minimum alveolar
concentration); DES+PIM-Inh.II, PIM-Inh.II in combination with
DES; IPOST, ischaemic postconditioning (three cycles of each 10-s
ischaemia/reperfusion); IPOST+PIM-Inh.II, PIM-Inh.II in combi-
nation with IPOST.
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Penna’s study31 are not directly comparable. More
recently, Borillo et al. demonstrated an increase in
mitochondrial Pim-1 levels after 30-min ischaemia
and 30-min reperfusion, and a corresponding
decrease in cytosolic Pim-1 levels after 30-min
ischaemia and 10-min reperfusion.32
Pim-1 kinase is known to phosphorylate the proa-
poptotic downstream molecule Bad specifically on
residue serine 112.33 This phosphorylation in turn
results in inactivation of Bad.33 A direct role for
Pim-1 in the prevention of cell death was suggested
because inactive Bad enhances Bcl-2 activity, which
promotes cell survival.33 Transgenic overexpression
of Pim-1 kinase in cardiomyocytes has been shown
to prevent apoptosis.18 In the present study, Pim-1
expression was not different among groups. There-
fore, the observed differences in phospho-BadSer112
expression can be more likely attributed to different
activity levels of Pim-1 kinase rather than different
Pim-1 expression levels. Our results demonstrate
that DES tends to increase phosphorylation of Bad at
serine 112, although this increase did not reach sta-
tistical significance. These results are consistent with
potential anti-apoptotic properties of the volatile
agent. DES-induced phosphorylation of Bad was
significantly reduced by pharmacological blockade
of Pim-1 kinase. These results imply an involvement
of Pim-1 kinase activation in the signalling cascade
of DES-induced postconditioning. However, IPOST
tends to decrease phosphorylation of Bad at serine
112, which was not affected by blockade of Pim-1
kinase, although this did not reach statistical signifi-
cance again. PIM-Inh.II alone did not affect phos-
phorylation of Bad at serine 112. Thus, it is currently
not clear whether phosphorylation of Bad at serine
112 by Pim-1 kinase is required for protection by
IPOST. Further studies are needed to address this
issue.
Bcl-2 protein is a key regulator of the apoptotic
cascade and is activated, among others, by phospho-
BadSer112.33 Activation of Bcl-2 prevents Cytochrome
C release into the cytosol,34 which is known to be an
early event of the apoptotic cascade.35 Overexpres-
sion of Bcl-2 in cardiac myocytes reduced
ischaemia-induced necrosis as well as apoptosis.36
Bcl-2 delays opening of the mitochondrial perme-
ability transition pore (mPTP).37 A crucial role for
mPTP has been demonstrated for APOST38,39 and
IPOST.40 Ischaemic and isoflurane-induced post-
conditioning are mediated by Bcl-2 in rabbits
because pharmacological inhibition of Bcl-2 with
HA14-1 abolished IS reduction by short cycles
of reperfusion/ischaemia or isoflurane exposure
during early reperfusion.29 In another study, isoflu-
rane enhanced Bcl-2 expression in neonatal rat
cardiac myocytes.41 IPC reduced apoptosis by an
induction of Bcl-2 gene in isolated rat hearts.42 Penna
et al. reported a decrease of both cytosolic and mito-
chondrial Bcl-2 levels by ischaemia/reperfusion
alone.31 IPOST attenuated this decrease and induced
a different redistribution of Bcl-2 between cytosolic
and mitochondrial fraction.31 Our data demonstrate
no differences in Bcl-2 expression among groups.
However, this is most probably due to our experi-
mental setting, where myocardial tissue for Western
immunoblotting was extracted after 1 h of reper-
fusion in contrast to 2 h in the study by Penna et al.31
Taken together with previous results,31,41 we suggest
that this time, window is too short to detect possible
differences in Bcl-2 expression.
The results of the current study should be inter-
preted within the constraint of several potential
limitations. PIM-Inh.II has been demonstrated to be
selective to Pim-1 kinase25 with high selectivity
over Pim-2 kinase. PIM-Inh.II was reported to have
a half maximal inhibitory concentration (IC50) for
Pim-1 kinase of 50 nM, whereas the IC50 for Pim-2
kinase was described to be > 20 mM.25 Nevertheless,
potential effects of PIM-Inh.II on Pim-2 and Pim-3
kinase and other kinases involved in the signalling
of either APOST or IPOST cannot be completely
excluded. We did not measure Pim-1 activity
directly. Phosphorylation of Bad at serine 112 was
used as a surrogate for Pim-1 activity. Pim-1 kinase
has been shown to specifically phosphorylate Bad
on serine 112.33 However, it cannot be excluded
that other kinases involved in postconditioning
cascades, particularly Akt, might phosphorylate
Bad on the same residue. However, it has been
described that Akt phosphorylates Bad predomi-
nantly at serine 136.43
Taken together, our results demonstrate that both
DES-induced postconditioning and IPOST against
myocardial infarction are mediated by the serine/
threonine kinase Pim-1. DES-induced postcondi-
tioning might induce some anti-apoptotic effects, at
least in part depending on Pim-1 activity. Thus, the
present findings further support the concept that
targeting anti-apoptotic proteins might be beneficial
in the treatment of myocardial ischaemia/
reperfusion injury.
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